COMMUNIQUÉS West-GlobeNewswire

Spectral AI Appoints Peter M. Carlson as CEO
29/02/2024
Appointment Paves the Way for Company’s Next Chapter in Commercialization Phase of AI-Powered DeepView Device for Predictive Wound Care Carlson Brings Proven Track Record of Operating and Financial Leadership, Including [...]
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
29/02/2024
WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
29/02/2024
Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company [...]
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
29/02/2024
Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time YARDLEY, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose [...]
Tarsus Announces Proposed $100.0 Million Public Offering
29/02/2024
IRVINE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to [...]
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
29/02/2024
MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of [...]
Theratechnologies annonce la démission de l’un de ses administrateurs, M. Alain Trudeau
29/02/2024
MONTRÉAL, 29 févr. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au point et la commercialisation [...]
Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results
29/02/2024
SOUTH ORANGE, NJ, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today [...]
Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference
29/02/2024
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its propri [...]
Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
29/02/2024
Nyxoah to Participate in the Oppenheimer 34 th Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgium – February 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“ [...]
Nyxoah Participera à la 34ème Oppenheimer Annual Healthcare MedTech & Services Conference
29/02/2024
Nyxoah Participera à la 34 ème Oppenheimer Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgique – 29 février 2024, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« [...]
CooperCompanies Announces First Quarter 2024 Results
29/02/2024
SAN RAMON, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2024. Revenue [...]
GENFIT Announces Revenues and Cash Position as of December 31, 2023
29/02/2024
Cash and cash equivalents totaled €77.8 million as of December 31, 2023 Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 million Upcoming FDA PDUFA action date for [...]
GENFIT annonce son chiffre d’affaires et sa position de trésorerie au 31 décembre 2023
29/02/2024
Trésorerie et équivalents de trésorerie : 77,8 millions d’euros au 31 décembre 2023 Chiffre d’affaires : 28,6 millions d’euros au 31 décembre 2023, dont un paiement d’étape de 13,3 millions d’euros Date d’action PDUFA [...]
RadNet Reports Fourth Quarter 2023 Results, Including Record Revenue and Adjusted EBITDA(1), Releases 2024 Financial Guidance and Forms a New Digital Health Reporting Segment
29/02/2024
Revenue increased 9.5% to a record $420.4 million in the fourth quarter of 2023 from $383.9 million in the fourth quarter of 2022; Excluding Revenue from the Artificial Intelligence (“AI”) reporting segment, Revenue [...]
Certara Reports Fourth Quarter 2023 Financial Results
29/02/2024
Provides Full Year 2024 Financial Guidance PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter [...]
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
29/02/2024
- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite - - Interim topline data from first-line RAS- [...]
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
29/02/2024
- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - - Company discontinued the [...]
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
29/02/2024
Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company [...]

Pages